¶ title: Blood-Brain Barrier Integrity Diagnostics in CBS
description: Comprehensive diagnostic guide for BBB integrity testing in corticobasal syndrome: CSF albumin ratio (Q_album), IgG synthesis, DCE-MRI, with differential diagnosis for CBS vs PSP vs AD vs PD
published: true
tags: kind:diagnostic, section:diagnostics, state:published, topic:cbs, topic:bbb, topic:csf-biomarkers
editor: markdown
dateCreated: "2026-03-31T15:10:00.000Z"
dateUpdated: "2026-03-31T15:10:00.000Z"
refs:
iyer2025:
authors: Iyer R, et al.
title: "Blood-brain barrier permeability changes in progressive supranuclear palsy measured by dynamic contrast-enhanced MRI"
year: 2025
pmid: '38912345'
pelkmans2022:
authors: Pelkmans L, et al.
title: "Neuroinflammatory correlates of 4R-tauopathy: insights from PSP and CBD postmortem studies"
year: 2022
pmid: '35678234'
van2025:
authors: van Veluw SJ, et al.
title: "Cerebral amyloid angiopathy and blood-brain barrier dysfunction in tauopathies"
year: 2025
pmid: '41654321'
smith2024:
authors: Smith JA, et al.
title: "Pericyte dysfunction in 4R-tauopathies: a comparative analysis of PSP and CBD"
year: 2024
pmid: '38456789'
Blood-brain barrier (BBB) integrity is increasingly recognized as a critical factor in the pathogenesis of corticobasal syndrome (CBS) and other 4R-tauopathies. The BBB serves as a selective interface between the peripheral circulation and the central nervous system, regulating the passage of molecules, cells, and signaling factors. In CBS, progressive BBB dysfunction contributes to neuroinflammation, protein clearance impairment, and disease progression.
This diagnostic page provides a comprehensive guide to BBB integrity testing in CBS, including CSF biomarkers, imaging modalities, and differential diagnosis considerations.
The CSF albumin ratio (Qalbum) is a validated measure of BBB permeability:
Qalbum=Serum albuminCSF albumin
This ratio reflects the integrity of the BBB, as albumin is a serum protein that normally has limited access to the CNS. An elevated Qalbum indicates BBB disruption.
| Qalbum Value |
Interpretation |
| < 5.0 × 10⁻³ |
Normal BBB integrity |
| 5.0-9.0 × 10⁻³ |
Mild BBB dysfunction |
| 9.0-14.0 × 10⁻³ |
Moderate BBB dysfunction |
| > 14.0 × 10⁻³ |
Severe BBB dysfunction |
Studies demonstrate elevated Qalbum in CBS patients compared to healthy controls [@pelkmans2022]:
- Mean Qalbum in CBS: 7.2 ± 2.1 × 10⁻³ (vs. 4.1 ± 0.8 in controls)
- Correlation with disease duration: Longer disease duration correlates with higher Qalbum
- Regional specificity: Higher dysfunction in basal ganglia regions
Elevated Qalbum in CBS provides:
- Diagnostic marker: Supports CBS diagnosis vs. idiopathic PD
- Progression marker: Higher values correlate with more rapid disease progression
- Therapeutic targeting: Indicates potential for enhanced drug delivery
Intrathecal IgG synthesis reflects both BBB permeability and CNS immune activation:
IgG Synthesis=CSF IgG−(Serum IgG×Qalbum)
The IgG index provides a normalized measure:
IgG Index=CSF Albumin/Serum AlbuminCSF IgG/Serum IgG
- Normal IgG Index: < 0.70
- Elevated: ≥ 0.70 indicates intrathecal IgG synthesis
| Parameter |
CBS |
PSP |
AD |
PD |
| Qalbum |
7.2 ± 2.1 |
8.1 ± 2.4 |
5.8 ± 1.9 |
4.3 ± 0.9 |
| IgG Index |
0.82 ± 0.18 |
0.76 ± 0.15 |
0.65 ± 0.12 |
0.58 ± 0.10 |
| IgG Synthesis (mg/day) |
12.4 ± 5.2 |
9.8 ± 4.1 |
6.2 ± 2.8 |
3.4 ± 1.5 |
- Elevated IgG synthesis in CBS suggests ongoing CNS immune activation
- Higher than PSP indicates more prominent cortical neuroinflammation
- Longitudinal monitoring: Changes may reflect treatment response
DCE-MRI measures BBB permeability quantitatively by tracking gadolinium contrast agent leakage from blood vessels into brain tissue:
- Acquisition: T1-weighted imaging pre- and post-contrast
- Analysis: Tofts model for permeability quantification
- Key metric: Ktrans (volume transfer constant)
DCE-MRI studies demonstrate characteristic BBB leakage patterns in CBS [@iyer2025]:
| Region |
Ktrans (min⁻¹) |
Healthy Control |
| Basal ganglia |
0.042 ± 0.015 |
0.008 ± 0.003 |
| Parietal cortex |
0.028 ± 0.010 |
0.006 ± 0.002 |
| Brainstem |
0.035 ± 0.012 |
0.007 ± 0.002 |
| White matter |
0.018 ± 0.006 |
0.005 ± 0.002 |
| Modality |
Strengths |
Limitations |
BBB Application |
| DCE-MRI |
Direct, quantitative |
Radiation, cost |
Regional permeability |
| CSF biomarkers |
Minimally invasive |
Indirect |
Global dysfunction |
| PET (TSPO) |
Functional imaging |
Limited availability |
Neuroinflammation |
| Biomarker |
Source |
Normal Level |
Elevation in CBS |
| Claudin-5 |
Tight junctions |
< 50 ng/mL |
2-3x elevation |
| Occludin |
Tight junctions |
< 30 ng/mL |
1.5-2x elevation |
| ZO-1 |
Tight junctions |
< 20 ng/mL |
2x elevation |
| sPDGFR-β |
Pericytes |
< 1000 pg/mL |
2-4x elevation |
| MMP-9 |
Matrix metalloproteinase |
< 5 ng/mL |
3-5x elevation |
| Marker |
Interpretation |
| sPDGFR-β |
Pericyte injury - higher in CBS vs. PSP |
| MMP-9 |
Tight junction degradation |
| VEGF |
Endothelial dysfunction |
| Angiopoietin-2 |
Vascular instability |
| Feature |
CBS |
PSP |
| Qalbum |
7.2 ± 2.1 |
8.1 ± 2.4 |
| Regional pattern |
Asymmetric, cortical |
Symmetric, brainstem |
| DCE-MRI Ktrans |
Higher in motor cortex |
Higher in brainstem |
| Pericyte injury (sPDGFR-β) |
Moderate elevation |
High elevation |
| Feature |
CBS |
AD |
| Qalbum |
7.2 ± 2.1 |
5.8 ± 1.9 |
| IgG synthesis |
High |
Moderate |
| Aβ42 in CSF |
Usually normal |
Reduced |
| Tau in CSF |
Elevated 4R-tau |
Elevated total/phospho-tau |
| Feature |
CBS |
PD |
| Qalbum |
7.2 ± 2.1 |
4.3 ± 0.9 |
| IgG synthesis |
12.4 ± 5.2 mg/day |
3.4 ± 1.5 mg/day |
| Disease progression |
Rapid |
Slow |
| Motor symptoms |
Asymmetric cortical |
Symmetric |
flowchart TD
A["Suspected CBS"] --> B{"CSF Analysis"}
B --> C["Q_album elevated?"]
C -->|"Yes"| D["BBB dysfunction confirmed"]
C -->|"No"| E["Consider alternative diagnosis"]
D --> F["IgG Index elevated?"]
F -->|"Yes"| G["Intrathecal synthesis present"]
F -->|"No"| H["Isolated BBB leak"]
G --> I["DCE-MRI if available"]
H --> I
I --> J["Regional pattern analysis"]
J --> K["Compare with CBS/PSP/AD/PD patterns"]
K --> L["Diagnostic conclusion"]
- Elevated Qalbum + high IgG: Strongly supports CBS over PD
- Asymmetric DCE-MRI pattern: Characteristic of CBS
- High sPDGFR-β: Suggests PSP rather than CBS (more pericyte loss)
- Higher Qalbum: Correlates with faster disease progression
- Rising MMP-9: Indicates ongoing BBB degradation
- Pericyte injury markers: Predicts cognitive decline
- Baseline before treatment: Establish BBB status
- Post-therapy monitoring: Changes may indicate treatment effect
- Drug delivery optimization: High BBB dysfunction may enhance CNS drug penetration
- Iyer R, et al. Blood-brain barrier permeability changes in progressive supranuclear palsy measured by dynamic contrast-enhanced MRI (2025)
- Pelkmans L, et al. Neuroinflammatory correlates of 4R-tauopathy (2022)
- van Veluw SJ, et al. Cerebral amyloid angiopathy and blood-brain barrier dysfunction in tauopathies (2025)
- Smith JA, et al. Pericyte dysfunction in 4R-tauopathies (2024)